• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Microarray-Based CGH in Cancer

        互联网

        769
        The detection of chromosome imbalances in malignancies has been a popular and useful approach in understanding key genetic loci and the molecular pathways of carcinogenesis. Alterations in gene dosage constitutes a major mechanism that leads to an imbalance in the gene products of oncogenes or tumor suppressor genes, resulting in the loss of normal cell division. One of the more robust technologies employed for determining alterations in gene dosage has been termed “comparative genomic hybridization” (CGH). CGH is a method that measures relative DNA copy differences between hybridized test DNA labeled with one fluorophore and reference DNA labeled in a spectrally distinct fluorophore. It was developed over a decade ago by Kallioniemi et al., who applied it to the study of copy number changes, in cancer cell lines and bladder tumors (1 ). Two limitations of CGH technology are the inability to detect balanced changes, such as translocations and inversions, and the necessity for tumor purity (≥80%). Collectively, CGH studies done over the past decade have demonstrated that certain regions are more frequently altered. Moreover, the patterns of alterations seen in different cancers are not the same. As tumors progress, the frequency of copy number changes increase so that as much as 50% of the genome of solid tumors can be aberrant. Most of these changes are secondary effects because of the cell’s inability to replicate and segregate its chromosomes in a normal fashion.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序